Steve Bender
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Angiogenesis and VEGF in Cancer, Cancer Treatment and Pharmacology, HER2/EGFR in Cancer Research, PI3K/AKT/mTOR signaling in cancer
Most-Cited Works
- → Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)(2011)909 cited
- → Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3(2008)623 cited
- → PF-03732010: A Fully Human Monoclonal Antibody against P-Cadherin with Antitumor and Antimetastatic Activity(2010)74 cited
- → Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation(2013)44 cited
- → Design, Synthesis, and Biological Activity of Novel Polycyclic Aza-Amide FKBP12 Ligands(2006)22 cited
- → Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacy(2008)12 cited
- → Prinomastat: A Potent and Selective Matrix Metalloprotease Inhibitor–Preclinical and Clinical Development for Oncology(2003)12 cited
- → Abstract 1733: EGF816, a novel covalent inhibitor of mutant-selective epidermal growth factor receptor, overcomes T790M-mediated resistance in NSCLC(2014)10 cited
- AG-028262, a novel selective VEGFR tyrosine kinase antagonist that potently inhibits KDR signaling and angiogenesis in vitro and in vivo(2004)
- → Abstract LB-390: Antitumor efficacy of crizotinib (PF-02341066), a potent and selective ALK and c-Met RTK inhibitor, in EML4-ALK driven NSCLC tumors in vitro and in vivo(2011)4 cited